Tumor-derived Factors Responsible for Dendritic Cell dysfunction

View/ Open
Author(s)
Pinzon-Charry, A
López, JA
Griffith University Author(s)
Year published
2009
Metadata
Show full item recordAbstract
Perpetuation of immune-deficiency throughout tumour development is, to a great degree, the result of impairment of DC function by products secreted by tumours. They include cytokines, non-tumour specific molecules (gangliosides, prostanoids, nitric oxide, etc) and tumour (specific) antigens (MUC-1, PSA, Her-2 neu). They may engender a distortion of DC development, block DC maturation, induce DC apoptosis or interfere with antigen presentation. Identifying those molecules and their interaction with DC will accelerate the development of more efficient immunotherapies. In this chapter we review the current literature on these ...
View more >Perpetuation of immune-deficiency throughout tumour development is, to a great degree, the result of impairment of DC function by products secreted by tumours. They include cytokines, non-tumour specific molecules (gangliosides, prostanoids, nitric oxide, etc) and tumour (specific) antigens (MUC-1, PSA, Her-2 neu). They may engender a distortion of DC development, block DC maturation, induce DC apoptosis or interfere with antigen presentation. Identifying those molecules and their interaction with DC will accelerate the development of more efficient immunotherapies. In this chapter we review the current literature on these interactions and highlight the possible avenues of minimisation of their deleterious effects.
View less >
View more >Perpetuation of immune-deficiency throughout tumour development is, to a great degree, the result of impairment of DC function by products secreted by tumours. They include cytokines, non-tumour specific molecules (gangliosides, prostanoids, nitric oxide, etc) and tumour (specific) antigens (MUC-1, PSA, Her-2 neu). They may engender a distortion of DC development, block DC maturation, induce DC apoptosis or interfere with antigen presentation. Identifying those molecules and their interaction with DC will accelerate the development of more efficient immunotherapies. In this chapter we review the current literature on these interactions and highlight the possible avenues of minimisation of their deleterious effects.
View less >
Book Title
Dendritic Cells in Cancer
Copyright Statement
© 2009 Springer. The attached file is reproduced here in accordance with the copyright policy of the publisher. The original publication is available at www.springerlink.com
Subject
Tumour immunology